Ozmosi | AL-3117 Drug Profile
Drug Profile
Using advanced filters...
Advanced Search [+]

AL-3117

Alternative Names: AL-3117, AL3117, AL 3117
Clinical Status: Active
Latest Update: 2026-07-17
Latest Update Note: Clinical Trial Update

Product Description

(Sourced from: https://www.azcuris.com/sub/pipeline.php)

Mechanisms of Action: TSLP Regulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Azcuris
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 0: Dermatitis, Atopic

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title